TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2721343

Group type: EXPERIMENTAL
Intervention: Glucometer M Diabetes Management System (experimental group)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Meters without memory (control group)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Both groups (experimental and control)
Number of subjects: 57
Study: 808089

Group type: EXPERIMENTAL
Intervention: Pediatric preparations of penicillin V (1 mill I.U.)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Group 1 (mixtures)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Group 2 (effervescent tablets, substance for drops and granulate)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All preparations
Number of subjects: 10
Study: 30295912

Group type: EXPERIMENTAL
Intervention: Iyengar Yoga (twice-weekly for 8 weeks)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Wellness classes (control)
Number of subjects: 227
Study: 28627125

Group type: EXPERIMENTAL
Intervention: 15-week physical exercise intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls (not specified as intervention or control)
Number of subjects: 0
Study: 26862085

Group type: EXPERIMENTAL
Intervention: Gaze-contingent attention training (120 min total, spread over six sessions)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Gaze-contingent attention training
Number of subjects: 27
Study: 25404436

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 21918851

Group type: EXPERIMENTAL
Intervention: MRI (including magnetic resonance angiography)
Number of subjects: 67
Study: 19104366

Group type: EXPERIMENTAL
Intervention: Increased access to emergency contraception (two free packs at enrollment with unlimited free resupply)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased access to emergency contraception
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard access to emergency contraception
Number of subjects: 0
Study: 17684704

Group type: EXPERIMENTAL
Intervention: Intraoperative 0.02% mitomycin-C (MMC) for 5 min
Number of subjects: 80

Group type: COMPARATOR
Intervention: Limbal-conjunctival autograft (LCAG)
Number of subjects: 80
Study: 15592925

Group type: EXPERIMENTAL
Intervention: Felodipine ER tablet (10 mg) with menthol (100 mg initially, followed by 50 mg, 25 mg, and 25 mg at specified intervals)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Felodipine ER tablet (10 mg) with placebo
Number of subjects: 11
Study: 14607627

Group type: EXPERIMENTAL
Intervention: Detection of AFPmRNA in HCC patients
Number of subjects: 126

Group type: COMPARATOR
Intervention: Detection of AFPmRNA in control subjects
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Correlation of AFPmRNA presence with metastasis
Number of subjects: 126
Study: 10211846

Group type: EXPERIMENTAL
Intervention: Exercise (EX) for 90 min at 58+/‐5% of maximal O2 uptake
Number of subjects: 8

Group type: COMPARATOR
Intervention: Rest (RE) without exercise
Number of subjects: 8
Study: 7616402

Group type: EXPERIMENTAL
Intervention: Intranasal cocaethylene administration
Number of subjects: 8

Group type: COMPARATOR
Intervention: Cocaine (as a comparator)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cocaethylene
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cocaethylene and cocaine
Number of subjects: 8
Study: 2619791

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 149

Group type: COMPARATOR
Intervention: No sedation
Number of subjects: 149
Study: 1088916

Group type: EXPERIMENTAL
Intervention: Combination of methyldopa and hydrochlorothiazide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methyldopa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 0
Study: 31613178

Group type: EXPERIMENTAL
Intervention: guselkumab
Number of subjects: 1803
Study: 31911261

Group type: EXPERIMENTAL
Intervention: Low dose prednisone (0.5 mg/kg/day for 6 months, max 30 mg daily) and methotrexate (15-20 mg once weekly for 6 months)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Standard dose prednisone (20 mg daily for 1 month, then 10 mg daily for 1 month, then 5 mg daily for one month then stop)
Number of subjects: 97
Study: 29697354

Group type: EXPERIMENTAL
Intervention: Bipolar cautery of lymphatic vessels
Number of subjects: 60

Group type: COMPARATOR
Intervention: Suture ligature
Number of subjects: 60
Study: 28505543

Group type: EXPERIMENTAL
Intervention: Apple polyphenols (AP) 600mg/day for 12 weeks
Number of subjects: 65
Study: 26383214

Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV) at 10 cmH2O
Number of subjects: 50

Group type: COMPARATOR
Intervention: Pressure Support Ventilation (PSV) at 14 cmH2O
Number of subjects: 50
Study: 22819549

Group type: EXPERIMENTAL
Intervention: 75 g of glucose
Number of subjects: 40

Group type: COMPARATOR
Intervention: Tap water (control)
Number of subjects: 40
Study: 21355146

Group type: EXPERIMENTAL
Intervention: Moxibustion at Zusanli (ST 36) and Sanyinjiao (SP 6)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Routine western medicine
Number of subjects: 97
Study: 18579901

Group type: EXPERIMENTAL
Intervention: Low-drop exercise (LD) group performing single-leg drop-landings from 14 cm, 3 sessions/week, 50 landings/session
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: High-drop exercise (HD) group performing single-leg drop-landings from 28 cm, 3 sessions/week, 50 landings/session
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Combined data from both exercise groups (LD and HD)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 42
Study: 16441739

Group type: EXPERIMENTAL
Intervention: beta-TCP+0.3 mg/ml of rhPDGF-BB
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: beta-TCP+1.0 mg/ml of rhPDGF-BB
Number of subjects: 47

Group type: COMPARATOR
Intervention: beta-TCP osteoconductive scaffold alone (active control)
Number of subjects: 47
Study: 12900807

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTF) 1,200 mg/d for 4 months
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (15 healthy individuals)
Number of subjects: 45
Study: 10871195

Group type: EXPERIMENTAL
Intervention: Combined model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deconvolution method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simplified deconvolution method
Number of subjects: 0

Group type: COMPARATOR
Intervention: C-peptide kinetics with somatostatin infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: C-peptide kinetics without somatostatin infusion
Number of subjects: 0
Study: 9093336

Group type: EXPERIMENTAL
Intervention: Nurse-led home management training programme (n = 96)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control group (n = 105)
Number of subjects: 201
Study: 8472735

Group type: EXPERIMENTAL
Intervention: 5,000 IU unfractionated heparin
Number of subjects: 155

Group type: COMPARATOR
Intervention: 5,000 IU unfractionated heparin + 0.5 mg dihydroergotamine mesylate twice daily
Number of subjects: 155
Study: 3829464

Group type: EXPERIMENTAL
Intervention: Modified cellulose (MC, 1.2 m2)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Regenerated cellulose (RC, 1.2 m2)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cellulose acetate (CA, 1.0 m2)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Modified cellulose (MC)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Regenerated cellulose (RC)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cellulose acetate (CA)
Number of subjects: 10
Study: 29360661

Group type: EXPERIMENTAL
Intervention: Palbociclib plus letrozole
Number of subjects: 666

Group type: COMPARATOR
Intervention: Placebo plus letrozole
Number of subjects: 666
Study: 26914104

Group type: EXPERIMENTAL
Intervention: Acupuncture-like transcutaneous electrical nerve stimulation (ALTENS) administered over 12 weeks (24 sessions)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Oral pilocarpine (PC) 5 mg three times daily over 12 weeks
Number of subjects: 137
Study: 25902100

Group type: EXPERIMENTAL
Intervention: Electro-oculogram recordings with mydriasis
Number of subjects: 55

Group type: COMPARATOR
Intervention: Electro-oculogram recordings without mydriasis
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Age influence on Arden ratio, dark-trough, light-peak
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Comparison of tested eyes
Number of subjects: 55
Study: 23377066

Group type: EXPERIMENTAL
Intervention: Freehand method
Number of subjects: 54

Group type: COMPARATOR
Intervention: Computer-aided methods
Number of subjects: 54
Study: 20497149

Group type: EXPERIMENTAL
Intervention: Airtraq
Number of subjects: 100

Group type: COMPARATOR
Intervention: lightwand
Number of subjects: 100
Study: 18504081

Group type: EXPERIMENTAL
Intervention: C804A polymorphism in the LTA gene
Number of subjects: 5804
Study: 15897673

Group type: EXPERIMENTAL
Intervention: low dose (S)-ketamine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: high dose (S)-ketamine
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 12617378

Group type: EXPERIMENTAL
Intervention: Abdominal vibration using a percutaneous bladder stimulator (Queen Square Bladder Stimulator; Malem Medical)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Abdominal pressure
Number of subjects: 28

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Comparison between abdominal pressure and vibration
Number of subjects: 28
Study: 10575269

Group type: EXPERIMENTAL
Intervention: Isoniazid (300 mg o.d. for 3 days)
Number of subjects: 160

Group type: COMPARATOR
Intervention: BCG (81 mg, 6 weekly instillations)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Isoniazid
Number of subjects: 160

Group type: COMPARATOR
Intervention: BCG
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Isoniazid and BCG
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo and BCG
Number of subjects: 160
Study: 8811474

Group type: EXPERIMENTAL
Intervention: GTR with self supporting membranes combined with the modified papilla preservation technique (group A)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Conventional guided tissue regeneration (GTR) with non‐resorbable expanded polytetrafluoroethilene (ePTFE) membranes (group B)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Access flap (group C)
Number of subjects: 45
Study: 1585760

Group type: EXPERIMENTAL
Intervention: Short-contact therapy with 1% Micanol, average application time 13 minutes, increased to 2.5% and 185 minutes after six weeks
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Long-contact therapy with 0.1% Micanol, average application time 8 hours, increased to 0.33% and 14 hours after six weeks
Number of subjects: 49
Study: 3907742

Group type: EXPERIMENTAL
Intervention: Amitriptyline (tricyclic)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mianserin (tetracyclic)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30735234

Group type: COMPARATOR
Intervention: LBS-only group (larger bonus size only)
Number of subjects: 8118

Group type: COMPARATOR
Intervention: LBS plus ISP group (larger bonus size + increased social pressure)
Number of subjects: 8118

Group type: COMPARATOR
Intervention: LBS plus LA group (larger bonus size + loss aversion)
Number of subjects: 8118
Study: 29433442

Group type: EXPERIMENTAL
Intervention: Psychological intervention
Number of subjects: 3845

Group type: EXPERIMENTAL
Intervention: Psychotropic medications
Number of subjects: 3845

Group type: EXPERIMENTAL
Intervention: Referral to specialist services
Number of subjects: 3845
Study: 26908127

Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel® (LAN) 120 mg every 4 weeks for 96 weeks
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study: 25728101

Group type: EXPERIMENTAL
Intervention: Cryotherapy with nitrous oxide gas
Number of subjects: 30

Group type: COMPARATOR
Intervention: Topical corticosteroids (triamcinolone acetonide 0.1% ointment in orabase)
Number of subjects: 30
Study: 23095934

Group type: EXPERIMENTAL
Intervention: Maraviroc (MVC) + Combivir
Number of subjects: 876

Group type: COMPARATOR
Intervention: Efavirenz (EFV) + Combivir
Number of subjects: 876

Group type: EXPERIMENTAL
Intervention: Maraviroc (MVC)
Number of subjects: 876

Group type: EXPERIMENTAL
Intervention: Maraviroc (MVC) and Efavirenz (EFV)
Number of subjects: 876

Group type: EXPERIMENTAL
Intervention: Genotype and ESTA screening
Number of subjects: 876
Study: 19364444

Group type: EXPERIMENTAL
Intervention: Experimental intervention
Number of subjects: 288

Group type: COMPARATOR
Intervention: Control (knowledge only) intervention
Number of subjects: 288
Study: 18006208

Group type: EXPERIMENTAL
Intervention: L-theanine (250 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caffeine (150 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of L-theanine and caffeine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 16202779

Group type: EXPERIMENTAL
Intervention: Early diagnosis through newborn screening (NBS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not screened)
Number of subjects: 0
Study: 11978277

Group type: EXPERIMENTAL
Intervention: GnRH agonist + daily norethindrone acetate 5 mg
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: GnRH agonist + daily norethindrone acetate 5 mg and conjugated equine estrogens 0.625 mg
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: GnRH agonist + daily norethindrone acetate 5 mg and conjugated equine estrogens 1.25 mg
Number of subjects: 123

Group type: COMPARATOR
Intervention: GnRH agonist + daily placebo
Number of subjects: 123
Study: 10590325

Group type: EXPERIMENTAL
Intervention: HPV6b VLPs without adjuvant
Number of subjects: 32
Study: 9348142

Group type: EXPERIMENTAL
Intervention: Bulkforming agent (Volcolon: psyllium fibres)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Auranofin 6 mgr daily
Number of subjects: 269
Study: 8444411

Group type: EXPERIMENTAL
Intervention: Interferon-alpha plus zidovudine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: COMPARATOR
Intervention: Interferon-alpha
Number of subjects: 24
Study: 2878461

Group type: EXPERIMENTAL
Intervention: lormetazepam (0.06 mg/kg) with Ro 15‐1788 (0.1 mg/kg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: flunitrazepam (0.03 mg/kg) with Ro 15‐1788 (0.1 mg/kg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo with Ro 15‐1788 (0.1 mg/kg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ro 15‐1788 (0.1 mg/kg) 24 h after BZ treatment
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Behavioural responses under BZ treatment
Number of subjects: 18
Study: 29808433

Group type: EXPERIMENTAL
Intervention: Individual CBT and workplace meeting (intervention)
Number of subjects: 137

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 137
Study: 26363806

Group type: COMPARATOR
Intervention: 0.25% bupivacaine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine
Number of subjects: 40
Study: 24895285

Group type: EXPERIMENTAL
Intervention: Acipimox
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 20561061

Group type: EXPERIMENTAL
Intervention: Traditional Flask (TF)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Experimental Flask (DF)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Experimental Flask (HHF)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (TF) vs Experimental (HHF)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (TF) vs Experimental (DF)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (DF) vs Experimental (HHF)
Number of subjects: 30
Study: 20488494

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Endoscopic treatment
Number of subjects: 203

Group type: COMPARATOR
Intervention: Surveillance only (Control)
Number of subjects: 203
Study: 18411236

Group type: EXPERIMENTAL
Intervention: Dichloroacetate
Number of subjects: 36
Study: 15921807

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 2498

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2498
Study: 12427851

Group type: EXPERIMENTAL
Intervention: Blind individuals
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sighted individuals
Number of subjects: 19
Study: 10477323

Group type: EXPERIMENTAL
Intervention: 200 mg carbamazepine immediate release tablets in SLS (1% sodium lauryl sulfate in water)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 200 mg carbamazepine immediate release tablets in HC (0.1 mol/l Hydrochloric acid in water)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Specification for dissolution testing in SLS
Number of subjects: 4

Group type: COMPARATOR
Intervention: USP specification for dissolution testing
Number of subjects: 4
Study: 8943962

Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg daily
Number of subjects: 1145

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg daily
Number of subjects: 1145

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily
Number of subjects: 1145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1145
Study: 1850682

Group type: EXPERIMENTAL
Intervention: Adrenaline infusion (30 ng min‐1 kg‐1)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Supine bicycle exercise
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 16
Study: 31438936

Group type: EXPERIMENTAL
Intervention: Rapid Cycle Deliberate Practice (RCDP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional simulation
Number of subjects: 0
Study: 27351077

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 100
Study: 25758472

Group type: EXPERIMENTAL
Intervention: Atacicept (150mg) administered twice weekly for 4 weeks, then once weekly for 32 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Atacicept
Number of subjects: 34
Study: 23680243

Group type: EXPERIMENTAL
Intervention: CSII
Number of subjects: 34

Group type: COMPARATOR
Intervention: MDI
Number of subjects: 34
Study: 21829595

Group type: EXPERIMENTAL
Intervention: Maintenance dose pegylated-IFNα for an additional 3.5 years
Number of subjects: 29

Group type: COMPARATOR
Intervention: No additional therapy group
Number of subjects: 29
Study: 19735787

Group type: EXPERIMENTAL
Intervention: Concurrent music during gait tasks in PD patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Concurrent music during gait tasks in control subjects
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dual-task with concurrent music in PD patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dual-task with concurrent music in control subjects
Number of subjects: 20
Study: 17826646

Group type: EXPERIMENTAL
Intervention: Levosimendan (LS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 15195496

Group type: EXPERIMENTAL
Intervention: Men instructed to wash hands before masturbation
Number of subjects: 93

Group type: COMPARATOR
Intervention: Men not instructed to wash hands before masturbation
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Effect of semen contamination on fertilization rate and embryo quality
Number of subjects: 93
Study: 11477282

Group type: EXPERIMENTAL
Intervention: Active physiotherapy
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Muscle reconditioning on training devices
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Low-impact aerobics
Number of subjects: 148
Study: 9713038

Group type: EXPERIMENTAL
Intervention: Selenium enriched yeast (4.8 mg containing 5 micrograms selenium daily)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Non-supplemented group
Number of subjects: 36
Study: 7985832

Group type: EXPERIMENTAL
Intervention: Heparin flushing three times/day by hospital IV team (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Heparin 1 mL of 2500 units in each lumen after dialysis three times/week by dialysis nurses (Group B)
Number of subjects: 40
Study: 2525101

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide, 800 micrograms twice daily via a Nebuhaler for 16 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (healthy volunteers and sarcoid patients)
Number of subjects: 10
Study: 30943553

Group type: EXPERIMENTAL
Intervention: 3-day low-residue diet (LRD)
Number of subjects: 390

Group type: COMPARATOR
Intervention: 1-day low-residue diet (LRD)
Number of subjects: 390
Study: 27441549

Group type: EXPERIMENTAL
Intervention: Incredible Years Teacher Classroom Management program (IY TCM)
Number of subjects: 1818

Group type: COMPARATOR
Intervention: Control, business as usual condition
Number of subjects: 1818
Study: 26563011

Group type: EXPERIMENTAL
Intervention: Betahistine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Trimetazidine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract
Number of subjects: 100

Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 100
Study: 23572200

Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acid intake
Number of subjects: 4680

Group type: EXPERIMENTAL
Intervention: Oleic acid from vegetable sources
Number of subjects: 4680
Study: 21242741

Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil 1200 mg administered once daily at 5 pm; dose adjustments to 600 or 1800 mg were permitted based on investigator judgment.
Number of subjects: 573
Study: 18506025

Group type: EXPERIMENTAL
Intervention: Cisplatin plus pemetrexed (n = 862)
Number of subjects: 1725

Group type: COMPARATOR
Intervention: Cisplatin plus gemcitabine (n = 863)
Number of subjects: 1725

Group type: COMPARATOR
Intervention: Cisplatin plus gemcitabine (n = 473)
Number of subjects: 1725

Group type: EXPERIMENTAL
Intervention: Cisplatin plus pemetrexed
Number of subjects: 1725

Group type: COMPARATOR
Intervention: Cisplatin plus gemcitabine
Number of subjects: 1725
Study: 16228238

Group type: EXPERIMENTAL
Intervention: Endoscopic third ventriculostomy
Number of subjects: 182

Group type: COMPARATOR
Intervention: Shunting
Number of subjects: 182
Study: 12974680

Group type: EXPERIMENTAL
Intervention: Genomic fingerprinting of mutans streptococci strains
Number of subjects: 16